Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sanofi (SNY) Tax Provisions (2016 - 2026)

Sanofi's Tax Provisions history spans 16 years, with the latest figure at -$491.7 million for Q1 2026.

  • On a quarterly basis, Tax Provisions rose 2.82% to -$491.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$3.6 billion, a 26.5% decrease, with the full-year FY2025 number at $1.2 billion, down 5.63% from a year prior.
  • Tax Provisions hit -$491.7 million in Q1 2026 for Sanofi, up from -$1.2 billion in the prior quarter.
  • Over the last five years, Tax Provisions for SNY hit a ceiling of -$113.0 million in Q1 2024 and a floor of -$1.6 billion in Q3 2025.
  • Historically, Tax Provisions has averaged -$654.2 million across 5 years, with a median of -$506.0 million in 2025.
  • Biggest five-year swings in Tax Provisions: surged 77.07% in 2024 and later plummeted 347.82% in 2025.
  • Tracing SNY's Tax Provisions over 5 years: stood at -$928.4 million in 2022, then dropped by 17.86% to -$1.1 billion in 2023, then fell by 17.58% to -$1.3 billion in 2024, then rose by 5.63% to -$1.2 billion in 2025, then surged by 59.5% to -$491.7 million in 2026.
  • Business Quant data shows Tax Provisions for SNY at -$491.7 million in Q1 2026, -$1.2 billion in Q4 2025, and -$1.6 billion in Q3 2025.